CoChat

BAD Phosphorylation Determines Ovarian Cancer Chemosensitivity and Patient Survival

Open access
Marchion, Douglas C., Cottrill, Hope M., Xiong, Yin, Chen, Ning, Bicaku, Elona, Fulp, William J., Bansal, Nisha, Chon, Hye Sook, Stickles, Xiaomang B., Kamath, Siddharth G., Hakam, Ardeshir, Li, Lihua, Su, Dan, Moreno, Carolina, Judson, Patricia L., Berchuck, Andrew, Wenham, Robert M., Apte, Sachin M., Gonzalez-Bosquet, Jesus, Bloom, Gregory C., Eschrich, Steven A., Sebti, Said, Chen, Dung-Tsa, Lancaster, Johnathan M. · 2011 · Clinical Cancer Research
Cited by 100

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Purpose: Despite initial sensitivity to chemotherapy, ovarian cancers (OVCA) often develop drug resistance, which limits patient survival. Using specimens and/or genomic data from 289 patients and a panel of cancer cell lines, we explored genome-wide expression changes that underlie the evolution of OVCA chemoresistance and characterized the BCL2 antagonist of cell death (BAD) apoptosis pathway as a determinant of chemosensitivity and patient survival. Experimental Design: Serial OVCA cell cisplatin treatments were performed in parallel with measurements of genome-wide expression changes. Pathway analysis was carried out on genes associated with increasing cisplatin resistance (EC50). BAD-pathway expression and BAD protein phosphorylation were evaluated in patient samples and cell lines as determinants of chemosensitivity and/or clinical outcome and as therapeutic targets. Results: Induced in vitro OVCA cisplatin resistance was associated with BAD-pathway expression (P < 0.001). In OVCA cell lines and primary specimens, BAD protein phosphorylation was associated with platinum resistance (n = 147, P < 0.0001) and also with overall patient survival (n = 134, P = 0.0007). Targeted modulation of BAD-phosphorylation levels influenced cisplatin sensitivity. A 47-gene BAD-pathway score was associated with in vitro phosphorylated BAD levels and with survival in 142 patients with advanced-stage (III/IV) serous OVCA. Integration of BAD-phosphorylation or BAD-pathway score with OVCA surgical cytoreductive status was significantly associated with overall survival by log-rank test (P = 0.004 and P < 0.0001, respectively). Conclusion: The BAD apoptosis pathway influences OVCA chemosensitivity and overall survival, likely via modulation of BAD phosphorylation. The pathway has clinical relevance as a biomarker of therapeutic response, patient survival, and as a promising therapeutic target. Clin Cancer Res; 17(19); 6356–66. ©2011 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-11-0735

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 100

Metadata

Authors
Marchion, D. C., Cottrill, H. M., Xiong, Y., Chen, N., Bicaku, E., Fulp, W. J., Bansal, N., Chon, H. S., Stickles, X. B., Kamath, S. G., Hakam, A., Li, L., Su, D., Moreno, C., Judson, P. L., Berchuck, A., Wenham, R. M., Apte, S. M., Gonzalez-Bosquet, J., Bloom, G. C., Eschrich, S. A., Sebti, S., Chen, D.-T., & Lancaster, J. M.
Venue
Clinical Cancer Research
Published
2011-10-01
Volume
17
Issue
19
Pages
6356-6366
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W4241297146
Cited by
100
References
2
FWCI
6.74
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: BAD Phosphorylation Determines Ovarian Cancer Chemosensitivity and Patient Survival. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-11-0735
The paper
Marchion, D. C., Cottrill, H. M., Xiong, Y., Chen, N., Bicaku, E., Fulp, W. J., Bansal, N., Chon, H. S., Stickles, X. B., Kamath, S. G., Hakam, A., Li, L., Su, D., Moreno, C., Judson, P. L., Berchuck, A., Wenham, R. M., Apte, S. M., Gonzalez-Bosquet, J., . . . Lancaster, J. M. (2011). BAD Phosphorylation Determines Ovarian Cancer Chemosensitivity and Patient Survival. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-11-0735

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.